Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.
Altered macrophage functions contribute to the pathogenesis of many infectious, immunological and inflammatory disease processes. Pharmacological modulation of macrophage activities therefore represents an important strategy for the prevention and treatment of inflammation-related diseases, such as atherosclerosis. This review focuses on recent advances on the role of the peroxisome proliferator-activated receptor transcription factor family in the modulation of lipid homeostasis and the inflammatory response in macrophages and the potential participation of these actions in the modulation of metabolic and cardiovascular disease.
Département d'Athérosclérose, Institut Pasteur de Lille, Lille, France.
M A
MA
Bouhlel
B
B
Staels
G
G
Chinetti-Gbaguidi
D050197:Atherosclerosis / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002784:Cholesterol / Q000378:metabolism*; D002986:Clinical Trials as Topic; D011345:Fenofibrate / Q000009:adverse effects / Q000627:therapeutic use; D015248:Gemfibrozil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists / Q000187:drug effects / Q000502:physiology
D000960:Hypolipidemic Agents; D047492:Peroxisome Proliferator-Activated Receptors; D002784:Cholesterol; D015248:Gemfibrozil; D011345:Fenofibrate